2004
Increase in Sexual Risk Behavior Associated with Immunologic Response to Highly Active Antiretroviral Therapy among HIV-Infected Injection Drug Users
Tun W, Gange S, Vlahov D, Strathdee S, Celentano D. Increase in Sexual Risk Behavior Associated with Immunologic Response to Highly Active Antiretroviral Therapy among HIV-Infected Injection Drug Users. Clinical Infectious Diseases 2004, 38: 1167-1174. PMID: 15095224, DOI: 10.1086/383033.Peer-Reviewed Original ResearchConceptsInjection drug usersActive antiretroviral therapyHAART initiationCell countAntiretroviral therapyDrug usersSexual intercourseRisk reduction counselingHuman immunodeficiency virusLarge cohort studyDrug injection behaviorInjection of drugsUnprotected sexual intercourseSemiannual visitsReduction counselingCohort studyHIV infectionHIV serostatusImmunodeficiency virusImmunologic responseNeedle sharingBlood samplesSurvival analysisRisk behaviorsCD4
2001
Influence of Injection Drug Use Behavior on Reported Antiretroviral Therapy Use Among Women in the HIV Epidemiology Research Study: On-Site Versus Referral Care.
Rompalo A, Shah N, Mayer K, Schuman P, Klein R, Smith D, Vlahov D. Influence of Injection Drug Use Behavior on Reported Antiretroviral Therapy Use Among Women in the HIV Epidemiology Research Study: On-Site Versus Referral Care. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 28. PMID: 11579274, DOI: 10.1097/00042560-200109010-00005.Peer-Reviewed Original ResearchConceptsInjection drug useInjection drug usersAntiretroviral therapy useAntiretroviral therapyART useDrug usersDrug useHIV careTherapy useSelf-reported injection drug useMedical careCD4 cell count categorySelf-reported ART useActive injection drug usersSexual contactFemale injection drug usersInjection drug use behaviorsPneumocystis carinii prophylaxisActive antiretroviral therapyProspective cohort studyHIV Epidemiology Research StudyHealth care providersCross-sectional analysisDrug use behaviorsReferral careImprovement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy
Semba R, Shah N, Vlahov D. Improvement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 26: 315-319. PMID: 11317071, DOI: 10.1097/00126334-200104010-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnemiaAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBaltimoreBody Mass IndexCD4 Lymphocyte CountChronic DiseaseFemaleHemoglobinsHIV InfectionsHIV-1HumansLongitudinal StudiesMaleMultivariate AnalysisPrevalenceSex FactorsSubstance Abuse, IntravenousViral LoadConceptsInjection drug usersPlasma HIV loadActive antiretroviral therapyAntiretroviral therapyHIV loadOpportunistic infectionsCopies/Mean decreaseDrug usersHIV-positive injection drug usersPotent antiretroviral therapyImprovement of anemiaBody mass indexIncrease of hemoglobinAntiretroviral medicationsHIV infectionMass indexControl subjectsOverall prevalenceChronic diseasesAnemiaNutritional statusMean increaseMultivariate analysisHAARTInitial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men
Sterling T, Vlahov D, Astemborski J, Hoover D, Margolick J, Quinn T. Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. New England Journal Of Medicine 2001, 344: 720-725. PMID: 11236775, DOI: 10.1056/nejm200103083441003.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-HIV AgentsCD4 Lymphocyte CountDisease ProgressionDisease-Free SurvivalEligibility DeterminationFemaleHIV AntibodiesHIV InfectionsHIV-1HumansLongitudinal StudiesMalePractice Guidelines as TopicRegression AnalysisReverse Transcriptase Polymerase Chain ReactionRiskRNA, ViralSex FactorsViral LoadConceptsInitial viral loadMedian initial viral loadHIV-1 RNAViral loadLymphocyte countHuman immunodeficiency virus type 1 (HIV-1) infectionPlasma HIV-1 RNA levelsHIV-1 RNA levelsHIV-1 RNA copiesFemale injection drug usersVirus type 1 infectionHIV-1 seroconversionMedian initial CD4Risk of progressionHIV-1 infectionType 1 infectionInjection drug usersLikelihood of progressionRate of progressionAntiretroviral therapyInitial CD4Hazard ratioAntiretroviral treatmentTreatment guidelinesImmunodeficiency syndrome
2000
Palliative care for HIV disease in the era of highly active antiretroviral therapy
Greenberg B, Mccorkle R, Vlahov D, Selwyn P. Palliative care for HIV disease in the era of highly active antiretroviral therapy. Journal Of Urban Health 2000, 77: 150-165. PMID: 10855997, PMCID: PMC3456123, DOI: 10.1007/bf02390527.Peer-Reviewed Original ResearchImproved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-326. DOI: 10.1097/00042560-200004010-00006.Peer-Reviewed Original ResearchConceptsHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsPotent antiretroviral therapyInjecting Drug UsersExcess oxidative stressOxidative stress levelsΒ-cryptoxanthinAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceΑ-tocopherolSerum αDrug useImproved antioxidant status among HIV-infected injecting drug users on potent antiretroviral therapy.
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved antioxidant status among HIV-infected injecting drug users on potent antiretroviral therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-6. PMID: 10836754, DOI: 10.1097/00126334-200004010-00006.Peer-Reviewed Original ResearchConceptsHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsSerum alpha-tocopherol levelsAlpha-tocopherolPotent antiretroviral therapyAlpha-tocopherol levelsExcess oxidative stressOxidative stress levelsAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceDrug useHIV
1999
Evaluating supervised haart in late-stage HIV among drug users: A preliminary report
Greenberg B, Berkman A, Thomas R, Hoos D, Finkelstein R, Astemborski J, Vlahov D. Evaluating supervised haart in late-stage HIV among drug users: A preliminary report. Journal Of Urban Health 1999, 76: 468-480. PMID: 10609596, PMCID: PMC3456696, DOI: 10.1007/bf02351504.Peer-Reviewed Original ResearchConceptsInjection drug usersResidential health care facilitiesViral load increaseViral loadDrug usersMean age 42 yearsHepatitis C virus antibodyHuman immunodeficiency virus (HIV) infectionActive antiretroviral therapyC virus antibodyTreatment-experienced patientsImmunodeficiency virus infectionAge 42 yearsHistory of dementiaLate-stage HIVHealth care facilitiesHIV/AIDSHCV seropositivityAntiretroviral therapyInitial CD4IDU populationRecord reviewSupervised therapyVirus antibodiesMedication administrationAccess to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group.
Carrieri M, Moatti J, Vlahov D, Obadia Y, Reynaud-Maurupt C, Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. Journal Of Epidemiology & Community Health 1999, 53: 4. PMID: 10326045, PMCID: PMC1756774, DOI: 10.1136/jech.53.1.4.Peer-Reviewed Original ResearchConceptsActive injection drug usersInjection drug usersAntiretroviral treatmentFrench HIVDrug useDrug usersFormer injection drug usersDetailed clinical historyPast drug useEx-IDUsIDU patientsClinical stageClinical historyAIDS careHospital careAIDS specialistsCell countNew treatmentsRisk behaviorsHospital departmentsLogistic regressionHIVPatientsPhysiciansTreatment
1998
Self-reported Antiretroviral Therapy in Injection Drug Users
Celentano D, Vlahov D, Cohn S, Shadle V, Obasanjo O, Moore R. Self-reported Antiretroviral Therapy in Injection Drug Users. JAMA 1998, 280: 544-546. PMID: 9707145, DOI: 10.1001/jama.280.6.544.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusInjection drug usersSelf-reported ART useAntiretroviral therapyART useDrug usersCombination therapyProtease inhibitorsRecent human immunodeficiency virusSelf-reported antiretroviral therapyInternational AIDS Society-USACurrent drug injectorsRecent antiretroviral therapyProtease inhibitor useHalf of patientsUS Public Health ServiceTriple combination therapyCommunity-based clinicsProportion of subjectsHealth care providersCurrent drug useActive drug usersCross-sectional surveyPublic health servicesInhibitor use
1997
Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
Rezza G, Galai N, Pezzotti P, Vlahov D, Graham N, Viale P, Angarano G. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study. Antiviral Therapy 1997, 2: 167-74. PMID: 11322271.Peer-Reviewed Original ResearchConceptsCD4 cell countInitiation of treatmentZidovudine monotherapyP24 antigenaemiaCell countConstitutional symptomsHIV seroconvertersRisk groupsCopies/Human immunodeficiency virus seroconvertersPlasma RNA viral loadHIV RNA copiesCD4 cell declineRNA viral loadStart of therapyMarker of responseAntigen-positive individualsAdditional predictive informationIndicator of responseStandard survival methodsTerms of progressionAntiretroviral therapyViral loadAntigen levelsDisease progression